The human microbiome market was valued at USD 599 million in 2021, and it is expected to witness a CAGR of 15.04% during the forecast period.
The human microbiome has become an area of interest in recent times because of its association with several respiratory diseases and immunity. The gut microbiome has been known to be associated with good immunity. Researchers have reported that variation in the number of microorganisms, such as actinobacteria, firmicute, and Bacteroidetes, leads to the development of lung, respiratory, diabetes, arthritis, gastrointestinal disorders, and other neurological disorders. In 2020, as per the article published in Human Microbiome Journal, "Lung microbiome and COVID-19: Possible link and implications", lung microbiome can profoundly impact the severity of the disease and susceptibility to the SARS-CoV-2 infection. Also, the study suggested that the lung microbiome plays a crucial role in the generation of immune responses against viral attacks, and the microbiome may affect the outcome of COVID-19. Thus, increasing research studies in the microbiome are the key drivers affirming the growth of this market.
Other key factors propelling the growth of this market are the increasing burden of lifestyle-related diseases and the growing geriatric population. Lowering the level of microbiota will lead to the growth of fatal infectious diseases and organisms, such as ulcerative colitis. C and Clostridium difficile (C. difficile). Antimicrobial resistance (AMR) in people taking antibiotics for a prolonged period is also helping the market to grow. For instance, as per the data published by the Centers for Disease Control and Prevention, in the United States, around 2.8 million antibiotic-resistant infections occur each year. Also, 223,900 cases of Clostridioides difficile occurred in 2017, and around 12,800 people died. As a result of increasing cases, the market is expected to increase in the upcoming years.
Increasing funding initiatives and government programs to support this research are high-impact rendering drivers anticipated to foster market growth. In 2019, the Million Microbiome of Humans Project (MMHP) was launched at China's 14th International Conference on Genomics (ICG-14).
However, lack of comprehensive research and stringent government regulations are likely to limit the market growth over the forecast period.
Microbiome therapeutics found a broad range of applications in COVID-19, Inflammatory Bowel Disease (IBD), C. difficile infections, Crohn’s disease, and diabetes. Rising research activities undertaken by research institutes for finding more therapeutic applications of the human microbiome are expected to accentuate the growth.
For instance, in 2020, the University of Zurich investigated the microbiota in COVID-19 patients for future preventive and therapeutic approaches (MICRO-COV). Positive results from these research studies will open up the growth avenues to the segment studied.
The Frontiers in Microbiology Journal article titled ‘Key Technologies for Progressing Discovery of Microbiome-Based Medicines’, published in June 2021, reported that human gastrointestinal microbiome research can deliver critical clinical and therapeutic development if it shifts toward mechanistic studies. It also suggested that the development of more efficacious and targeted treatments relies on identifying causal links between the microbiome and disease, with future progress dependent on effective links between state-of-the-art sequencing approaches, computational analyses, and experimental assays. Such studies drive the growth of the market.
The agreements and collaborations also boost market segment growth among the market players to strengthen their position in the market. For instance, in July 2021, Seres Therapeutics Inc. entered into an agreement with Nestlé Health Science to jointly commercialize SER-109, Seres’ investigational oral microbiome therapeutic for recurrent Clostridioides difficile infection (CDI) in the United States and Canada. This Investigational Microbiome Therapeutics will lead the way for an entirely new treatment modality.
All the factors mentioned above are likely to boost the segmental growth over the forecast period.
North America currently dominates the market for the human microbiome due to the rising incidences of lifestyle-related diseases and autoimmune disorders in these regions. A strong drug pipeline can also be attributed to the highly lucrative growth. For instance, in 2020, Seres Therapeutics' stool-derived treatment for recurrent Clostridium difficile infection cleared the phase-III of clinical trials.
In August 2019, the Stanford Microbiome Therapies Initiative (MITI), a joint initiative between Stanford ChEM-H and the Department of Bioengineering, was launched to harness the communities of microbes inhabiting human bodies.
As per an article in BioMed Central Journal, 2019, the National Institutes of Health (NIH) supports the microbiome project, with 21 out of 27 NIH institutes supporting and funding this area through extramural projects.
Also, in 2019, the Government of Canada announced an investment of USD 18 million for microbiome research. This investment may support seven research teams from across the country studying the microbiome to understand better its contribution to childhood asthma, cervical cancer, diabetes, youth inflammatory bowel disease, and maternal malnutrition. Thus, these research initiatives and rising government funding have established North America as one of the major markets in the human microbiome and helped this market to grow at a healthy rate.
The COVID-19 pandemic has highlighted the need for North American companies and research organizations to collaborate with the government to develop therapeutics and diagnostics to meet future health crises. Several universities and key players are focusing on developing interventions for coronavirus. In March 2020, Kaleido Biosciences initiated the controlled clinical study of microbiome metabolic therapy, KB109, in outpatients with mild-to-moderate COVID-19. Thus, it is expected to boost the market further studied over the forecast.
The human microbiome market is less competitive, and several players are coming up with new products. Companies like Yakult, DuPont, Series Therapeutics, Second Genome, and Synthetic Biologics hold substantial shares in the market. Key players are focusing on enhancing the therapeutics pipeline by developing efficient and safe drugs.
This product will be delivered within 2 business days.
The human microbiome has become an area of interest in recent times because of its association with several respiratory diseases and immunity. The gut microbiome has been known to be associated with good immunity. Researchers have reported that variation in the number of microorganisms, such as actinobacteria, firmicute, and Bacteroidetes, leads to the development of lung, respiratory, diabetes, arthritis, gastrointestinal disorders, and other neurological disorders. In 2020, as per the article published in Human Microbiome Journal, "Lung microbiome and COVID-19: Possible link and implications", lung microbiome can profoundly impact the severity of the disease and susceptibility to the SARS-CoV-2 infection. Also, the study suggested that the lung microbiome plays a crucial role in the generation of immune responses against viral attacks, and the microbiome may affect the outcome of COVID-19. Thus, increasing research studies in the microbiome are the key drivers affirming the growth of this market.
Other key factors propelling the growth of this market are the increasing burden of lifestyle-related diseases and the growing geriatric population. Lowering the level of microbiota will lead to the growth of fatal infectious diseases and organisms, such as ulcerative colitis. C and Clostridium difficile (C. difficile). Antimicrobial resistance (AMR) in people taking antibiotics for a prolonged period is also helping the market to grow. For instance, as per the data published by the Centers for Disease Control and Prevention, in the United States, around 2.8 million antibiotic-resistant infections occur each year. Also, 223,900 cases of Clostridioides difficile occurred in 2017, and around 12,800 people died. As a result of increasing cases, the market is expected to increase in the upcoming years.
Increasing funding initiatives and government programs to support this research are high-impact rendering drivers anticipated to foster market growth. In 2019, the Million Microbiome of Humans Project (MMHP) was launched at China's 14th International Conference on Genomics (ICG-14).
However, lack of comprehensive research and stringent government regulations are likely to limit the market growth over the forecast period.
Key Market Trends
Therapeutic Applications Expected to Hold the Highest Share Over the Forecast Period
Microbiome therapeutics found a broad range of applications in COVID-19, Inflammatory Bowel Disease (IBD), C. difficile infections, Crohn’s disease, and diabetes. Rising research activities undertaken by research institutes for finding more therapeutic applications of the human microbiome are expected to accentuate the growth.
For instance, in 2020, the University of Zurich investigated the microbiota in COVID-19 patients for future preventive and therapeutic approaches (MICRO-COV). Positive results from these research studies will open up the growth avenues to the segment studied.
The Frontiers in Microbiology Journal article titled ‘Key Technologies for Progressing Discovery of Microbiome-Based Medicines’, published in June 2021, reported that human gastrointestinal microbiome research can deliver critical clinical and therapeutic development if it shifts toward mechanistic studies. It also suggested that the development of more efficacious and targeted treatments relies on identifying causal links between the microbiome and disease, with future progress dependent on effective links between state-of-the-art sequencing approaches, computational analyses, and experimental assays. Such studies drive the growth of the market.
The agreements and collaborations also boost market segment growth among the market players to strengthen their position in the market. For instance, in July 2021, Seres Therapeutics Inc. entered into an agreement with Nestlé Health Science to jointly commercialize SER-109, Seres’ investigational oral microbiome therapeutic for recurrent Clostridioides difficile infection (CDI) in the United States and Canada. This Investigational Microbiome Therapeutics will lead the way for an entirely new treatment modality.
All the factors mentioned above are likely to boost the segmental growth over the forecast period.
North America Dominates the Market and Expected to do the Same Over the Forecast Period
North America currently dominates the market for the human microbiome due to the rising incidences of lifestyle-related diseases and autoimmune disorders in these regions. A strong drug pipeline can also be attributed to the highly lucrative growth. For instance, in 2020, Seres Therapeutics' stool-derived treatment for recurrent Clostridium difficile infection cleared the phase-III of clinical trials.
In August 2019, the Stanford Microbiome Therapies Initiative (MITI), a joint initiative between Stanford ChEM-H and the Department of Bioengineering, was launched to harness the communities of microbes inhabiting human bodies.
As per an article in BioMed Central Journal, 2019, the National Institutes of Health (NIH) supports the microbiome project, with 21 out of 27 NIH institutes supporting and funding this area through extramural projects.
Also, in 2019, the Government of Canada announced an investment of USD 18 million for microbiome research. This investment may support seven research teams from across the country studying the microbiome to understand better its contribution to childhood asthma, cervical cancer, diabetes, youth inflammatory bowel disease, and maternal malnutrition. Thus, these research initiatives and rising government funding have established North America as one of the major markets in the human microbiome and helped this market to grow at a healthy rate.
The COVID-19 pandemic has highlighted the need for North American companies and research organizations to collaborate with the government to develop therapeutics and diagnostics to meet future health crises. Several universities and key players are focusing on developing interventions for coronavirus. In March 2020, Kaleido Biosciences initiated the controlled clinical study of microbiome metabolic therapy, KB109, in outpatients with mild-to-moderate COVID-19. Thus, it is expected to boost the market further studied over the forecast.
Competitive Landscape
The human microbiome market is less competitive, and several players are coming up with new products. Companies like Yakult, DuPont, Series Therapeutics, Second Genome, and Synthetic Biologics hold substantial shares in the market. Key players are focusing on enhancing the therapeutics pipeline by developing efficient and safe drugs.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
This product will be delivered within 2 business days.
Table of Contents
1 INTRODUCTION
4 MARKET DYNAMICS
5 MARKET SEGMENTATION (Market Size by Value - USD Million)
6 COMPETITIVE LANDSCAPE
Companies Mentioned
A selection of companies mentioned in this report includes:
- AOBiome Therapeutics Inc
- Astarte Medical
- Axial Biotherapeutics
- DuPont
- Enterome Bioscience
- Evelo Biosciences
- Finch Therapeutics
- Ginkgo Bioworks
- Exeliom Biosciences SAS
- Osel Inc.
- Second Genome Inc.
- Seres Therapeutics
Methodology
LOADING...
